STAANasdaqOphthalmic GoodsFiscal year ends January 2
STAAR SURGICAL CO
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 12, 2026
$21.88+0.61 (+2.87%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 312.6
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
76.2%+3.8 pts over 5 years
Operating margin
-38.3%−42.4 pts over 5 years
Net margin
-33.6%−37.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -23.7% | 0.0% | +7.9% | +12.0% | |
| Gross profit | -23.9% | -6.5% | +9.0% | +13.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -31.6% | 3.3% | -21.7% | |
| Return on assets | -18.9% | 2.5% | -16.7% | |
| Current ratio | 2.35 | 5.25 | 4.55 | |
| Interest coverage | -113.0× | – | – | |
| Capex to revenue | 3.9% | 5.1% | 2.4% | |
| Diluted shares | 40M | 48M | 50M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Staar Surgical generated $144.23M from operations and spent $85.62M on capital expenditure, dividends and share buybacks. 92% of that went back into the business.
Generated
$144.23M
Used
$85.62M
Capital expenditure$79.16M92%Dividends$00%Share buybacks$6.46M8%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-33.6%
×Asset turnover0.50×
×Equity multiplier1.30×
=Return on equity, FY2025-21.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -33.6% | 0.50× | 1.30× | -21.7% |
| FY2024 | -6.4% | 0.63× | 1.27× | -5.2% |
| FY2023 | 6.6% | 0.71× | 1.26× | 5.9% |
| FY2022 | 16.6% | 0.63× | 1.28× | 13.3% |
| FY2021 | 11.9% | 0.76× | 1.31× | 12.0% |
| FY2020 | 3.6% | 0.70× | 1.30× | 3.3% |
| FY2019 | 9.4% | 0.80× | 1.28× | 9.6% |
| FY2018 | 4.0% | 1.05× | 1.34× | 5.7% |
| FY2017 | -2.4% | 1.36× | 1.65× | -5.3% |
| FY2016 | -14.7% | 1.28× | 1.67× | -31.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$80.45M
- Cash generatingOperating cash flow above zero-$34.23M
- Return on assets improvedROA up on the prior year-4.1% → -15.8%
- Earnings backed by cashOperating cash flow above net income-$34.23M vs -$80.45M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.23 → 4.55
- No dilutionShare count did not rise49M → 50M
- Gross margin improvedGross margin up on the prior year76.32% → 76.19%
- More efficientAsset turnover rose0.64 → 0.47